Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01494311 · ClinicalTrials.gov registry record · Phase 4
Rapydan Topical Anaesthesia for Arterial Cannulation
A Phase 4 study, sponsored by Medical University of Vienna.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT01494311: Completed Phase 4 study, sponsored by Medical University of Vienna.
NCT01494311 is a Phase 4 study that has completed, run by Medical University of Vienna. The registered enrollment target is 90 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01494311, a Phase 4 study, has completed, sponsored by Medical University of Vienna.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
Arterial catheterization is painful and is associated with patient stress and anxiety. Analgesia is usually provided by subcutaneous injection of local anesthetic. An alternative is topical anaesthesia, such as Rapydan which is a novel topical anesthetic patch containing 70 mg each of lidocaine and tetracaine. We therefore tested the hypothesis that Rapydan patch analgesia is non-inferior to subcutaneous local anesthetic.
Primary Outcome
After finishing the puncture procedure, patients were asked to rate their worst pain during subcutaneous injection, during insertion of arterial cannula, and one minute after catheter insertion using a 100-mm-long visual analog scale (VAS). The use of a VAS to measure pain and discomfort has been validated in the several settings of chronic pain, acute postoperative pain, and acute non-surgical pain.
Interventions
- DRUG Placebo Patch
- DRUG Lidocaine/tetracaine patch
- DRUG Subcutaneous injection of 0.5 ml Lidocain 1%
- DRUG Subcutaneous injection of saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-10 |
| Phase | Phase 4 |
What the finished NCT01494311 record still lists
NCT01494311 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo Patch is the first listed.
NCT01494311 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01494311 about?
NCT01494311 is a clinical study titled "Rapydan Topical Anaesthesia for Arterial Cannulation". Arterial catheterization is painful and is associated with patient stress and anxiety. Analgesia is usually provided by subcutaneous injection of local anesthetic. An alternative is topical anaesthesia, such as Rapydan which is a novel topical anesthetic patch containing 70 mg each of lidocaine and ...
What is the current status of trial NCT01494311?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2011-03. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01494311?
The interventions under investigation include: Placebo Patch (DRUG), Lidocaine/tetracaine patch (DRUG), Subcutaneous injection of 0.5 ml Lidocain 1% (DRUG), Subcutaneous injection of saline (DRUG).
Who is sponsoring clinical trial NCT01494311?
This trial is sponsored by Medical University of Vienna, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01494311's enrollment target sits among peer trials
90 886th of 2000 higher than 1,088 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia